Meeting
2018 Genitourinary Cancers Symposium
Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study.
Authors
Mamta Parikh
University of California Davis, Sacramento, CA
Mamta Parikh , Jasmine C Hyunh , Primo Lara Jr., Chong-xian Pan , Daniel Robles , Christopher P. Evans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02339168
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 281)
DOI
10.1200/JCO.2018.36.6_suppl.281
Abstract #
281
Poster Bd #
N13
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC).
First Author: Mamta Parikh
Poster
2013 ASCO Annual Meeting
A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC).
First Author: Jacek K. Pinski
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION).
First Author: Sarah Elizabeth Fenton
Poster
2020 Genitourinary Cancers Symposium
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa